骨保护素的临床应用

被引：8

作者：

关振宇 ^{[1
]}

赵学武 ^{[2
]}

艾纯华 ^{[1
]}

卞传华 ^{[1
]}

机构：

[1] 中国人民解放军第医院骨一科

[2] 中国人民解放军部队医院

来源：

吉林医学 | 2010年 / 31卷 / 16期

关键词：

骨保护素; 应用; 临床;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

<正>骨保护素(osteoprotegerin,OPG)是肿瘤坏死因子(tumor necrosis factor,TNF)受体家族的新成员,最初于1997年被两个独立的实验室同时发现,也被称为破骨细胞抑制因子(os-

引用

页码：2549 / 2552

页数：4

共 13 条

[1]

Activation of the p53 pathway down regulates the osteoprotegerin expression and release by vascular endothelial cells..Secchiero P;Corallini F;Rimondi E; et al;.Blood.2008, 03

[2]

Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis [J].

Asanuma, Yu ;

Chung, Cecilia P. ;

Oeser, Annette ;

Solus, Joseph F. ;

Avalos, Ingrid ;

Gebretsadik, Tebeb ;

Shintani, Ayumi ;

Raggi, Paolo ;

Sokka, Tuulikki ;

Pincus, Theodore ;

Stein, C. Michael .

ATHEROSCLEROSIS, 2007, 195 (02) :E135-E141

[3]

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction [J].

Secchiero, Paola ;

Corallini, Federica ;

Pandolfi, Assunta ;

Consoli, Agostino ;

Candido, Riccardo ;

Fabris, Bruno ;

Celeghini, Claudio ;

Capitani, Silvano ;

Zauli, Giorgio .

AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (06) :2236-2244

[4]

The RANK/RANKL/OPG triad in cancer-induced bone diseases [J].

Dougall, William C. ;

Chaisson, Michelle .

CANCER AND METASTASIS REVIEWS, 2006, 25 (04) :541-549

[5]

Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models [J].

Schett, G ;

Middleton, S ;

Bolon, B ;

Stolina, M ;

Brown, H ;

Zhu, L ;

Pretorius, J ;

Zack, DJ ;

Kostenuik, P ;

Feige, U .

ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1604-1611

[6]

The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women [J].

Mezquita-Raya, P ;

de la Higuera, M ;

García, DF ;

Alonso, G ;

Ruiz-Requena, ME ;

Luna, JD ;

Escobar-Jiménez, F ;

Muñoz-Torres, M .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (11) :1368-1374

[7]

Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis.[J].H.L. Neville-Webbe;N.A. Cross;C.L. Eaton;R. Nyambo;C.A. Evans;R.E. Coleman;I. Holen.Breast Cancer Research and Treatment.2004, 3

[8]

Arterial osteoprotegerin:: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α [J].

Olesen, P ;

Ledet, T ;

Rasmussen, LM .

DIABETOLOGIA, 2005, 48 (03) :561-568

[9]

Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha [J].

Wada, N ;

Maeda, H ;

Yoshimine, Y ;

Akamine, A .

BONE, 2004, 35 (03) :629-635

[10]

Single and combined inhibition of tumor necrosis factor; interleukin‐1; and RANKL pathways in tumor necrosis factor–induced arthritis: Effects on synovial inflammation; bone erosion; and cartilage destruction.[J].JochenZwerina;SilviaHayer;MakiyehTohidast‐Akrad;HelgaBergmeister;KurtRedlich;UlrichFeige;ColinDunstan;GiorgosKollias;GünterSteiner;JosefSmolen;GeorgSchett.Arthritis & Rheumatism.2004, 1

← 1 2 →